Open Access

Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment

  • Authors:
    • Fei Sun
    • Bo‑Qiang Cao
    • Bo Wang
    • Shi‑Qiang Wu
    • De‑Hua Jiang
  • View Affiliations

  • Published online on: July 27, 2016     https://doi.org/10.3892/etm.2016.3553
  • Pages: 1780-1784
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the study was to analyze the effect of ABCB1 genetic polymorphisms on the efficacy of phenytoin (PHT) treatment in epilepsy patients. In total, 200 epilepsy patients who were administered PHT were divided into the responsive and pharmaco-resistance groups depending on the clinical data of PHT treatment in epilepsy patients. The serum concentration of PHT was detected by high‑performance liquid chromatography (HPLC). ABCB1 polymorphisms were analyzed by the polymerase chain reaction restriction‑fragment length polymorphism method. The C1236T, C3435T and G2677T/A haplotypes were reconstructed for the ABCB1 gene using SHEsis programs. One‑way analysis of variance was used for data analysis. In ABCB1 C1236T, the rate of the CC genotype in pharmaco‑resistance (17.5%) was higher than that of the responsive group (2.1%), while the rate of the TT genotype in pharmaco‑resistance (41.6%) was lower than that of the responsive group (55.4%) (P<0.05). In ABCB1 G2677T/A, the rate of the GG genotype in pharmaco‑resistance (29.6%) was higher than that of the responsive group (9.7%), while the rate of the TT genotype in pharmaco‑resistance (4.6%) was lower than that of the responsive group (30.4%) (P<0.05). The rate of the TTC haploid in pharmaco-resistance (24.1%) was higher than that of the responsive group (8.8%) (P<0.05). The PHT serum concentration had no statistical significance in the patients with different genotypes. In conclusion, there was no association between ABCB1 genetic polymorphism and PHT serum concentration, although the polymorphisms affected the efficacy of PHT treatment in patients with epilepsy.
View References

Related Articles

Journal Cover

September-2016
Volume 12 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun F, Cao BQ, Wang B, Wu SQ and Jiang DH: Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment. Exp Ther Med 12: 1780-1784, 2016
APA
Sun, F., Cao, B., Wang, B., Wu, S., & Jiang, D. (2016). Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment. Experimental and Therapeutic Medicine, 12, 1780-1784. https://doi.org/10.3892/etm.2016.3553
MLA
Sun, F., Cao, B., Wang, B., Wu, S., Jiang, D."Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment". Experimental and Therapeutic Medicine 12.3 (2016): 1780-1784.
Chicago
Sun, F., Cao, B., Wang, B., Wu, S., Jiang, D."Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment". Experimental and Therapeutic Medicine 12, no. 3 (2016): 1780-1784. https://doi.org/10.3892/etm.2016.3553